Gapping up
In reaction to strong earnings/guidance: BSTG +35.7%, LXU +23%, JACK +10.8%, RVLT +9.5%, YRD +6.7%, CDXC +6.4%, SSRI +4.9%, RL +4.1%, MIDD +3.5%, NTES +2.9%, RDY +2.8%, HIMX +2.1%, DLA +2%, AER +1.9%, PBH +1.2%, CLLS +1%, NEOT +1%, PAAS +0.9%
M&A news:BLOX +17.6% (receives acquisition proposal from PE firm Thoma Bravo, according to Bloomberg), MON +13.7% (move attributed to M&A speculation with BASF (BASFY) as possible suitor; also reports Bayer (BAYRY) is mulling a bid)
Select EU financial related names showing strength: DB +1.9%, BCS +1.7% (upgraded - see below), BBVA +1.6%, ING +1.3%
Select oil/gas related names showing strength: SDRL +6.4%, RIG +2.6%, BP +2%, RDS.A +1.9%, MRO +1.9%
Other news: PBMD +15.8% (signs licensing agreement with Sydys to license CVac), BDSI +8.3% (BioDelivery Sciences signs a licensing agreement granting exclusive rights to devlop and commercialize Onsolis in the US to Collegium Pharma ) CHK +5.5% (enters into privately negotiated purchase and exchange agreements under which it has and will exchange shares of common stock for certain of its outstanding senior notes), POT +3.1% (in sympathy with MON), WTW +2.7% (Director Denis Kelly purchases 10,000 shares at prices from $12.14-12.22; shareholders elect Oprah Winfrey to Board), SCTY +2.5% (still checking), MOS +2.1% (in sympathy with MON), VRX +1.6% (Pershing Square Holdings releases Q1 letter to investors), IHG +1.2% (announced details of special dividend), AZN +1.1% (receives Orphan Drug Designation for Selumetinib), HZNP +0.9% (enters into a settlement and license agreement with Teligent (TLGT) to resolve pending patent litigation involving Pennsaid 2%)
Analyst comments: GPK +2.4% (initiated with a Conviction Buy at Goldman), BCS +1.7% (upgraded to Neutral from Underperform at Exane BNP Paribas), SNY +1.6% (upgraded to Overweight from Equal Weight at Barclays), BERY +0.8% (initiated with a Buy at Goldman)
In reaction to strong earnings/guidance: BSTG +35.7%, LXU +23%, JACK +10.8%, RVLT +9.5%, YRD +6.7%, CDXC +6.4%, SSRI +4.9%, RL +4.1%, MIDD +3.5%, NTES +2.9%, RDY +2.8%, HIMX +2.1%, DLA +2%, AER +1.9%, PBH +1.2%, CLLS +1%, NEOT +1%, PAAS +0.9%
M&A news:BLOX +17.6% (receives acquisition proposal from PE firm Thoma Bravo, according to Bloomberg), MON +13.7% (move attributed to M&A speculation with BASF (BASFY) as possible suitor; also reports Bayer (BAYRY) is mulling a bid)
Select EU financial related names showing strength: DB +1.9%, BCS +1.7% (upgraded - see below), BBVA +1.6%, ING +1.3%
Select oil/gas related names showing strength: SDRL +6.4%, RIG +2.6%, BP +2%, RDS.A +1.9%, MRO +1.9%
Other news: PBMD +15.8% (signs licensing agreement with Sydys to license CVac), BDSI +8.3% (BioDelivery Sciences signs a licensing agreement granting exclusive rights to devlop and commercialize Onsolis in the US to Collegium Pharma ) CHK +5.5% (enters into privately negotiated purchase and exchange agreements under which it has and will exchange shares of common stock for certain of its outstanding senior notes), POT +3.1% (in sympathy with MON), WTW +2.7% (Director Denis Kelly purchases 10,000 shares at prices from $12.14-12.22; shareholders elect Oprah Winfrey to Board), SCTY +2.5% (still checking), MOS +2.1% (in sympathy with MON), VRX +1.6% (Pershing Square Holdings releases Q1 letter to investors), IHG +1.2% (announced details of special dividend), AZN +1.1% (receives Orphan Drug Designation for Selumetinib), HZNP +0.9% (enters into a settlement and license agreement with Teligent (TLGT) to resolve pending patent litigation involving Pennsaid 2%)
Analyst comments: GPK +2.4% (initiated with a Conviction Buy at Goldman), BCS +1.7% (upgraded to Neutral from Underperform at Exane BNP Paribas), SNY +1.6% (upgraded to Overweight from Equal Weight at Barclays), BERY +0.8% (initiated with a Buy at Goldman)